Latest Breaking News On - Arch biopartners inc - Page 1 : comparemela.com

Baystreet.ca - U.S. Eases into Memorial Day Weekend

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 02, 2024 Arch Biopartners Inc., , announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and.

Arch Biopartners Adds Three New Clinical Sites into the

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that.

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

TORONTO, Feb. 27, 2024 Arch Biopartners Inc., , announced today that it had a pre-investigational new drug application meeting with the U.S. Food and Drug Administration Division of.